Compare SONO & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SONO | IOVA |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2018 | 2008 |
| Metric | SONO | IOVA |
|---|---|---|
| Price | $14.73 | $4.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $19.67 | $9.00 |
| AVG Volume (30 Days) | 2.2M | ★ 16.5M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $1,443,276,000.00 | N/A |
| Revenue This Year | $5.04 | $47.74 |
| Revenue Next Year | $6.53 | $40.31 |
| P/E Ratio | $27.94 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.12 | $1.76 |
| 52 Week High | $19.82 | $5.64 |
| Indicator | SONO | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 52.31 | 58.94 |
| Support Level | $12.77 | $3.77 |
| Resistance Level | $15.35 | $5.63 |
| Average True Range (ATR) | 0.70 | 0.40 |
| MACD | 0.08 | 0.07 |
| Stochastic Oscillator | 48.76 | 64.89 |
Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.